960 x 350_41

Discovery Bioanalysis

Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.


Q2 Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.


Specific strengths include:

  • ADME assay development (including drug-drug interaction testing, discovery and development metabolite identification, and in vitro ADME screening)
  • Ligand-binding assays
  • Pharmacokinetic (PK) testing
  • Immunogenicity testing and immunoassays
  • Biomarker assays
  • Large molecule bioanalysis and LC/MS bioanalysis
  • DMPK services

Q² Solutions can work with you to develop automated small molecule LC/MS assays, large molecule ligand binding assays, immunoassays, and large-molecule hybrid-LC/MS assays to meet your discovery bioanalysis needs.

Q² Solutions can help you design and carry out validated assays that will move your project forward

Component 89 – 49

Assay Development for Large-Scale Clinical Studies

Supporting data from high-volume, regulated clinical studies

Component 89 – 50

Large Molecule Bioanalytical and ADME Solutions

Solutions for your large molecule bioanalysis and the successful outcome you seek

Related Thought Leaders Insights

Preparation for Biotech Testing or Clinical Trials

Your clinical trial may involve samples from multiple sites to be tested by multiple laboratories. The data that flows from those tests may travel to multiple end users as well. Proper planning of...

Risk Management for Biotech Companies in Clinical Trials

  In this episode, the second of a three-part series, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Alan Wookey, Global Head of Companion Diagnostics discuss how to manage...

Bridging the Ligand Binding Assays and LC-MS Disciplines for Hybrid Assays

Assessing the pharmacokinetics of biologics presents several analytical challenges, from the use of critical reagents and assay sensitivity requirements to regulatory and throughput considerations....